These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32566037)

  • 41. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207.
    You L; Wang H; Yang G; Zhao F; Zhang J; Liu Z; Zhang T; Liang Z; Liu C; Zhao Y
    Mol Oncol; 2018 Dec; 12(12):2147-2164. PubMed ID: 30341811
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
    Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
    BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
    Wang W; Reiser-Erkan C; Michalski CW; Raggi MC; Quan L; Yupei Z; Friess H; Erkan M; Kleeff J
    Biochem Biophys Res Commun; 2010 Oct; 401(3):422-8. PubMed ID: 20863812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
    Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
    Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.
    Dong J; Zhao YP; Zhou L; Zhang TP; Chen G
    Arch Med Res; 2011 Jan; 42(1):8-14. PubMed ID: 21376256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
    Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
    Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
    Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
    Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M
    Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
    Fujino Y; Ueda T; Kamigaki T; Takase S; Ajiki T; Kamoda Y; Matsumoto I; Yasuda T; Kuroda Y
    Pancreas; 2007 Apr; 34(3):335-9. PubMed ID: 17414056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer.
    Xu JW; Wang TX; You L; Zheng LF; Shu H; Zhang TP; Zhao YP
    PLoS One; 2014; 9(3):e92847. PubMed ID: 24667580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
    Merz V; Zecchetto C; Santoro R; Simionato F; Sabbadini F; Mangiameli D; Piro G; Cavaliere A; Deiana M; Valenti MT; Bazan D; Fedele V; Lonardi S; Melisi D
    Clin Cancer Res; 2020 Sep; 26(17):4661-4669. PubMed ID: 32532788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
    Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
    Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer.
    Sonohara F; Yamada S; Takeda S; Hayashi M; Suenaga M; Sunagawa Y; Tashiro M; Takami H; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Anticancer Res; 2020 Apr; 40(4):1843-1853. PubMed ID: 32234872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.